Innate Pharma (IPHA) Net Margin (2019 - 2024)
Innate Pharma's (IPHA) quarterly Net Margin came in at 391.94% in Q4 2024, down 37736.0% YoY from N/an in Q1 2024, and down 31.25% on a QoQ basis from 298.61% in Q2 2024.
Innate Pharma (IPHA) Net Margin (2019 - 2024) Analysis & Trends
Innate Pharma (IPHA) has 6 years of Net Margin data on file, last reported at 391.94% in Q4 2024.
- Quarterly Net Margin fell 37736.0% year-over-year to 391.94% in Q4 2024, while the trailing twelve-month figure through Dec 2025 was 127.22% (down 5265.0% YoY) and the FY2025 annual result came in at 241.02%, down 28493.0% from the prior year.
- Net Margin eased to 391.94% in Q4 2024, from 298.61% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 887.05% in Q4 2021 to a low of 391.94% in Q4 2024.
- A 5-year average of 8.84% and a median of 7.5% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2021 — Net Margin surged 99952 bps — and 2022, when it plunged 88694 bps.
- Tracing IPHA's Net Margin over 5 years: stood at 112.47% in 2020, then jumped by 889 bps to 887.05% in 2021, then plunged by 100 bps to 0.11% in 2022, then tumbled by 13454 bps to 14.59% in 2023, then plunged by 2587 bps to 391.94% in 2024.
- The last three Net Margin figures came in at 391.94% (Q4 2024), 298.61% (Q2 2024), and 14.59% (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -1,764.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -391.94% |
| Jun 30, 2024 | -298.61% |
| Dec 31, 2023 | -14.59% |
| Jun 30, 2023 | 1.61% |
| Dec 31, 2022 | 0.11% |
| Jun 30, 2022 | -0.42% |
| Dec 31, 2021 | 887.05% |
| Dec 31, 2020 | -112.47% |
| Dec 31, 2019 | -30.10% |